Prostaglandin E-major urinary metabolite as a noninvasive surrogate marker for infantile necrotizing enterocolitis

Space: StayCurrentMD Author: Ken-ichiro Konishi, Mariko Yoshida, Atsushi Nakao, Keiji Tsuchiya, Chisa Tsurisawa, Kunihiko Ichiki, Tomohiro Takeda, Yoshiya Hisaeda, Atsushi Hirota, Shusuke Amagata, Takayuki Odashima, Kinji Yokomori, Kazuo Ishida, Masaaki Matsuura, Satoru Ito, Mutsunor Published: 2018-10-03

Author / Expert

Ken-ichiro Konishi, Mariko Yoshida, Atsushi Nakao, Keiji Tsuchiya, Chisa Tsurisawa, Kunihiko Ichiki, Tomohiro Takeda, Yoshiya Hisaeda, Atsushi Hirota, Shusuke Amagata, Takayuki Odashima, Kinji Yokomori, Kazuo Ishida, Masaaki Matsuura, Satoru Ito, Mutsunor

Topic overview

Abstract

Background

Early definitive diagnosis of necrotizing enterocolitis (NEC) based on Bell's staging criteria is difficult because there are few observable changes on abdominal imaging and blood chemistry tests at the onset of the disease.

Purpose

To investigate whether prostaglandin E-2 major urinary metabolite (PGE-MUM) can be a useful surrogate marker reflecting the disease state and severity of NEC in infants.

Methods

Infants were enrolled in this study between January 2014 and December 2016. NEC diagnosis was based on Bell's staging criteria > Stage II or necrotic bowel observed at surgery. After diagnosis, PGE-MUM level was measured and compared with that of the other disease and healthy infant groups.

Results

Median PGE-MUM value was highest in the NEC group (576 [65–3672] μg/g•Cre/BSA × 1000), followed by the other disease group (94 [57–296] μg/g•Cre/BSA × 1000) and the healthy infant group (19 [10–44] μg/g•Cre/BSA × 1000) (sensitivity: 92.3%, specificity: 81.5%, accuracy: 85.0%; p 